March 2022 in “International Journal of Trichology” Tofacitinib may be effective for treating hair loss caused by alopecia areata that doesn't respond to other treatments.
14 citations
,
April 2017 in “American Journal of Transplantation” Skin problems from transplant drugs are common and need careful management in organ transplant patients.
September 2023 in “Journal of the American Academy of Dermatology” CTP-543 is generally safe for treating alopecia areata.
25 citations
,
December 1991 in “The Journal of Dermatology” Cyclosporin A promotes hair growth in young nude mice.
July 2023 in “Skin Research and Technology” Baricitinib combined with other immune therapies may safely and effectively treat severe scalp hair loss.
April 2024 in “Clinical and experimental dermatology” Tofacitinib is effective for severe alopecia areata, similar to oral betamethasone.
3 citations
,
April 2016 in “Journal of Investigative Dermatology” Tofacitinib, a JAK inhibitor, improved hair regrowth in most patients with severe alopecia areata and had minimal side effects.
14 citations
,
January 2016 in “Annals of dermatology/Annals of Dermatology” Oral cyclosporine is more effective and safer than betamethasone for treating alopecia areata.
January 2024 in “International Journal of Dermatology Venereology and Leprosy Sciences” Tofacitinib may be safe and effective for treating certain skin conditions in children.
8 citations
,
January 1977 in “Acta Haematologica” The treatment was effective for advanced non-Hodgkin's lymphomas.
11 citations
,
June 2012 in “Archives of Dermatological Research” L-cystine and vitamin B6 at high doses prevented hair loss in mice treated with a chemotherapy drug.
January 2016 in “The Australian Pharmacist” Tofacitinib might be used to treat hair loss.
2 citations
,
January 2002 in “Linchuang pifuke zazhi” Cyclosporine combination therapy can regrow hair in severe alopecia areata but needs careful monitoring for side effects.
June 2020 in “Dermatologic therapy” Using Janus kinase inhibitors (JAKi) in COVID-19 treatment requires careful consideration due to their immunosuppressive effects.
20 citations
,
October 2003 in “The Journal of Dermatology” DCP therapy causes side effects like weakness, flushing, headaches, and taste changes, but less frequently causes hypertension and diabetes.
153 citations
,
January 2001 in “Science” Using CDK inhibitors on rats showed a reduction in chemotherapy-caused hair loss, but later experiments could not repeat these results.
80 citations
,
August 1991 in “The journal of allergy and clinical immunology/Journal of allergy and clinical immunology/The journal of allergy and clinical immunology” Methotrexate reduced the need for steroids in asthma patients without worsening their condition.
15 citations
,
August 2002 in “British Journal of Ophthalmology” Intralesional cidofovir might be a viable alternative treatment for certain conditions.
December 2025 in “JGH Open” Early diagnosis and treatment with corticosteroids can improve outcomes in Cronkhite–Canada syndrome.
December 2025 in “Indian Journal of Case Reports” Stopping azathioprine improved hair loss and bone marrow issues.
1 citations
,
October 2015 in “The American journal of gastroenterology” Stopping infliximab and using strong topical steroids can regrow hair lost due to psoriasiform alopecia.
Amotosalen-treated donor T-cells can prevent late CMV infection after bone marrow transplants.
8 citations
,
July 2020 in “Dermatologic Therapy” Tofacitinib may effectively treat folliculitis decalvans.
2 citations
,
February 2025 in “Free Radical Biology and Medicine” Blocking S100A8 can reduce chemotherapy-induced hair loss.
2 citations
,
April 2022 in “Cutaneous and Ocular Toxicology” Tofacitinib may help treat hair loss in children with alopecia areata.
February 2023 in “Reactions Weekly” 19 citations
,
September 2006 in “Journal of Pediatric Gastroenterology and Nutrition” Early use of infliximab in severe pediatric Crohn's disease can lead to significant improvement and remission.
1 citations
,
November 2016 in “Journal of dermatological treatment” Oral tacrolimus may be a potential treatment for hair loss that doesn't respond to corticosteroids.
4 citations
,
October 2018 in “JAMA Dermatology” Ruxolitinib may help treat hair loss and symptoms in patients with chronic graft-versus-host disease.
January 2024 in “Wiadomości Lekarskie” Enhancing immune response can improve cancer treatment effectiveness.